Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1381-1400 of 2,251 trials

Type 1 Diabetes: Diamyd® Treatment Study

We are evaluating the safety and feasibility of Diamyd® injections in young people at risk for Type 1 diabetes. This study looks at how the treatment affects their immune system and progression of the disease.

Type 1 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Rimegepant for Migraine: Effects on Obesity

We are studying how rimegepant affects migraine-related reactions in lean and obese individuals. The goal is to understand the relationship between body composition and migraine responses.

ObesityMigraine6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyNeurology

Skin Cancer Treatment: The BLESS Trial

We are investigating whether reducing the dose of bleomycin in electrochemotherapy can still effectively treat skin cancers. This study aims to see if patients can benefit from less medication while achieving similar tumor response.

Skin Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesDermatologyOncology

HIV-1 Treatment: High-Dose Antiretroviral Drugs

We are studying whether high doses of antiretroviral drugs can reduce the hidden HIV-1 reservoir in people living with HIV. This trial will also assess the safety and effects of the treatment on immune markers.

HIV Infection6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious Diseases

Behçet’s Disease Uveitis: Adalimumab vs. Tocilizumab

We are comparing two biologic treatments for severe uveitis in Behçet’s disease to see which one may better improve vision and reduce inflammation. This study will also evaluate the safety of both medications.

Severe Uveitis of Behçet’s Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOphthalmologyRheumatology

Breast Cancer: Palbociclib and Fulvestrant Combination

We are testing a combination of palbociclib and fulvestrant in women with advanced breast cancer who have not responded to prior treatments. The goal is to evaluate its effectiveness and safety for these patients.

Metastatic Breast CancerEfficacy phase (II)No PlaceboStandard MedicinesOncology

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Colorectal Cancer: PIPAC Treatment Study

We are testing a new chemotherapy method to prevent cancer spread in patients who have had surgery for high-risk colorectal cancer. This study will help us understand its effectiveness and impact on patients' quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Type 2 Diabetes: Comparing Empagliflozin, Pioglitazone, and Semaglutide

We are studying how different diabetes medications affect fat tissue function in people with type 2 diabetes. This research may help us understand which drug works best for improving health outcomes.

Type 2 Diabetes6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Cardiovascular Disease Prevention: Personalized Statin Therapy

We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.

High Genetic Risk for Coronary Artery Disease1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Omalizumab Withdrawal in Severe Allergic Asthma

We are studying whether stopping Omalizumab after long-term treatment is as effective as continuing it for patients with well-controlled severe allergic asthma. This trial aims to assess asthma control and quality of life over time.

Allergic Asthma1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

Pancreatic Cancer: Trametinib and Hydrochloroquine Study

We are exploring a new treatment combination for patients with metastatic pancreatic cancer to see if it helps improve survival and understand resistance to therapy. This study aims to assess safety and effectiveness while analyzing how the cancer may resist treatment.

Metastatic Pancreatic CancerEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

NK Cell Infusion for Sarcoma in Young Patients

We are testing a new immunotherapy using activated NK cells for children, adolescents, and young adults with refractory sarcomas. The goal is to evaluate its safety and effects after chemotherapy or radiotherapy.

Sarcomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Cancer Treatments: Impact on Speech and Quality of Life

We are studying how different cancer treatments affect speech understanding in noise and overall quality of life for patients. This research may help us understand the cognitive effects of these treatments over time.

Bladder CancerTesticular SeminomaHead and Neck Cancer≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesOncologyPsychiatry

Colon Cancer: Dostarlimab with CAPEOX

We are studying a new treatment combining dostarlimab with CAPEOX for people with untreated Stage III colon cancer. The goal is to see if this combination is more effective and safe compared to CAPEOX alone.

Metastatic Colon CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Recurrent Meningioma: [177Lu]Lu-DOTATATE Treatment Study

We are investigating whether [177Lu]Lu-DOTATATE can effectively treat recurrent meningioma compared to standard care. The study will also look at safety and quality of life for participants.

Meningioma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplantation: Donor Modified Immune Cells

We are studying whether using specially modified immune cells can help patients tolerate their new kidney better than standard treatments. The trial also looks at the safety of this new approach in preventing infections and other complications.

Kidney Transplant>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Acute Bacterial Prostatitis: Fosfomycin vs. Cefixime

We are comparing two oral antibiotics to see which one better resolves urinary symptoms in men with acute bacterial prostatitis. The study will also look at any side effects and the effectiveness of the treatments over time.

Acute Bacterial Prostatitis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesUrology

Multiple Sclerosis: Treatment Withdrawal Study for Older Adults

We are investigating whether stopping disease-modifying therapies is safe for people aged 55 and over with inactive relapsing-remitting multiple sclerosis. The study will help us understand its effects on relapse rates, disability, and quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology